Mindset Pharma Inc (OP:MSSTF)

N/A UNCHANGED

Last Price Updated: 3:55 PM EDT, Oct 24, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mindset Pharma Inc

< Previous 1 2 3 4 Next >

Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic ↗

September 18, 2023

Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic...

Via Benzinga

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions ↗

August 31, 2023

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka...

Via Benzinga

Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application ↗

July 18, 2023

As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also...

Via Benzinga

Reunion Neuroscience On The Brink Of Going Private With Final Court Approval ↗

July 17, 2023

Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution...

Via Benzinga

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3 ↗

June 29, 2023

Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the...

Via Benzinga

UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression ↗

June 27, 2023

Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K.

Via Benzinga

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗

May 01, 2023

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

Via Benzinga

This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection ↗

April 26, 2023

Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way.

Via Benzinga

New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market ↗

April 25, 2023

Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual...

Via Benzinga

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗

March 20, 2023

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

Via Benzinga

Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court ↗

March 14, 2023

Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey.

Via Benzinga

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More ↗

March 13, 2023

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

Via Benzinga

Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla ↗

March 06, 2023

The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia.

Via Benzinga

Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded ↗

February 03, 2023

Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders

Via Benzinga

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗

January 25, 2023

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

Via Benzinga

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News ↗

January 21, 2023

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for...

Via Benzinga

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗

November 21, 2022

Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy

Via Benzinga

These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details ↗

November 16, 2022

Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc.

Via Benzinga

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

November 16, 2022

PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers

From PharmAla Biotech

Via GlobeNewswire

EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance ↗

November 07, 2022

(Part four of a four-part series) See previous stories in this series:

Via Benzinga

European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed ↗

October 11, 2022

UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used...

Via Benzinga

Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More ↗

October 07, 2022

Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy

Via Benzinga

Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials ↗

October 07, 2022

Biopharma R&D company Mindset Pharma Inc.

Via Benzinga

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds

September 27, 2022

Via Investor Brand Network

Topics Intellectual Property

Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family ↗

September 27, 2022

Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.

Via Benzinga

Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close? ↗

September 14, 2022

Biotech drug discovery firm Mindset Pharma Inc.

Via Benzinga

Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries ↗

September 07, 2022

Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of...

Via Benzinga

Psychedelic Stock Gainers And Losers From September 7, 2022 ↗

September 07, 2022

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.66% at $1.12

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.